Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to trea... Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.33 | 11.301369863 | 2.92 | 3.25 | 2.9024 | 89464 | 3.1060382 | CS |
| 4 | 0.58 | 21.7228464419 | 2.67 | 4.2 | 2.57 | 452428 | 3.34977865 | CS |
| 12 | 2.08 | 177.777777778 | 1.17 | 4.2 | 1.146 | 695576 | 2.03537935 | CS |
| 26 | 2.01 | 162.096774194 | 1.24 | 4.2 | 1.12 | 330187 | 2.00925624 | CS |
| 52 | 1.92 | 144.360902256 | 1.33 | 4.2 | 1.12 | 215494 | 2.07448937 | CS |
| 156 | -5.51 | -62.899543379 | 8.76 | 10.8 | 0.79 | 196004 | 3.45411588 | CS |
| 260 | -60.77 | -94.9234614183 | 64.02 | 70.8 | 0.79 | 238365 | 9.610916 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
